Engflag

Reflu

Quick links to important sections

Reflu

Reflu_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reflu

Property Description
Active ingredient Fluconazole
Form Oral (Capsule, Tablet, Suspension), Intravenous (IV) Solution
Pharmacological class Systemic Antifungal Agent, Bis-triazole Derivative
General Purpose Management of mycosis (fungal infections)
Origin Synthetic drug

Reflu is a synthetic prescription medication whose core component is the active ingredient known as Fluconazole. Fluconazole is a systemic antifungal agent and is identified as a bis-triazole derivative within the broader azole class. This classification indicates the medicine is designed to work internally to manage fungal proliferation throughout the body, providing systemic coverage.

Composition and Available Pharmaceutical Forms

The medicine Reflu is formulated as a single-ingredient product, with its therapeutic properties stemming from the presence of Fluconazole. This active ingredient is prepared in several dosage form(s) to ensure systemic delivery. These include oral formulation preparations, such as the capsule, tablet, and powder for oral suspension. Furthermore, Reflu is manufactured as a solution for infusion, an intravenous (IV) preparation used for direct, controlled administration into the bloodstream. These distinct forms accommodate either the oral or intravenous route of administration to maintain drug levels in patients facing generalized infections.

What is the General Purpose of Taking Reflu?

The general purpose of Reflu is to control and manage various types of mycosis or fungal infections by limiting the pathogen's growth and replication. The drug functions as a selective inhibitor that interferes with a biological process in the fungal cell—the production of ergosterol, an essential component of the fungal membrane. By disrupting the cell membrane's integrity, Reflu exerts a fungistatic effect, which stops the proliferation of the fungal cells. A typical use scenario involves the medication being used for the management of an internal infection caused by Candida species.

What side effects are possible with Reflu?

Official Safety Profile and Adverse Reactions

The safety profile for Reflu (Fluconazole) is structured in regulatory documents to classify potential adverse reactions based on frequency and affected body system. This classification helps in understanding the documented risks associated with the medicine.

Frequency-Classified Adverse Reactions

The most frequently documented effects are classified as Common and typically involve the Gastrointestinal and Nervous Systems. These often include headache, nausea, vomiting, diarrhea, and abdominal pain. Effects classified as Uncommon include insomnia, dizziness, and certain skin reactions like pruritus (itching) and urticaria (hives).

Serious Adverse Reactions

Official labels highlight rare but serious adverse reactions that require close attention. These include Severe Hepatic Toxicity and Hepatic Failure, which have been reported in patients, though reversibility upon discontinuation is common. Other serious events include severe exfoliative skin disorders, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The medication is also associated with rare Cardiac Events, specifically QT prolongation and Torsade de Pointes, particularly in patients with pre-existing cardiac risk factors.

Safety Considerations and Limitations

Regulatory documentation notes specific constraints for use. Dose adjustment is required for patients with renal impairment. Caution is advised when administering Reflu to patients with pre-existing hepatic impairment or those with factors predisposing them to cardiac arrhythmias. Discontinuation of therapy is noted as necessary if signs suggestive of severe hepatic disease or bullous skin lesions develop. Serious hepatic and skin reactions have been reported without a clear relationship to total daily dose or duration.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Reflu (Fluconazole) is defined by severe, documented effects on the central nervous system (CNS). Clinical manifestations detailed in official regulatory documents include the acute onset of hallucinations and pronounced paranoid behavior. Overdose also carries the risk of severe neurological outcomes, specifically the occurrence of seizures (convulsions), which require urgent intervention.

Any suspected or confirmed overdose situation requires that individuals seek immediate medical attention. This action is strictly mandated by government regulatory guidance, which advises contacting a poison control center immediately to report the incident and obtain direction.

Management and Emergency Procedures

The official regulatory profile confirms that no specific antidote is known to reverse the effects of Fluconazole overdose. Consequently, the standard clinical management described in regulatory documents focuses exclusively on providing symptomatic treatment and general supportive measures based on the patient’s clinical status. For recent, acute ingestions, gastric lavage may be considered as a procedure. Additionally, regulatory information notes that hemodialysis is an effective measure for removal, capable of reducing Fluconazole plasma concentrations significantly, and is a recognized part of severe overdose management under hospital observation.

Therapeutic Uses of Reflu

What Reflu Treats: Main Uses and Benefits

The primary therapeutic role of Reflu (Fluconazole) is the management of a wide array of fungal infections, and its application falls within established therapeutic domains.

Reflu is considered relevant as a therapeutic option for managing severe fungal diseases that pose high physiological stress, such as infections in the bloodstream (candidemia) or the central nervous system (Cryptococcal Meningitis). Its benefit is the clearance of the systemic infection and it is commonly used to help with managing high systemic burden. It supports recovery during acute, disruptive episodes.

Reflu may be applied in contexts involving fungal overgrowth on mucous membranes, such as oral thrush, Esophageal Candidiasis, and vaginal yeast infections. Reflu contributes to relief from clustered symptoms of soreness, burning, and intense itching, assisting with maintaining functional stability and helping improve day-to-day comfort.

The drug is relevant in conditions presenting with acute episodes, including invasive infections; for localized fungal conditions; and as suppressive therapy to prevent relapse in highly vulnerable patients. The therapeutic focus supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.

“The medication supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.”

Quick Fact: Relief for Localized Discomfort

Reflu is considered relevant for easing symptoms related to inflammatory or irritative states caused by fungal presence, specifically providing supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Reflu

The eligibility profile for Reflu is strictly defined by regulatory documents, which establish specific populations for whom the medicine is contraindicated (prohibited) or not recommended.

Contraindicated Populations:

Official labeling mandates that Reflu must not be used in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Use is also strictly prohibited for any individual who has experienced a prior serious hypersensitivity or allergic reaction to the active substance or to any of the other product components.

Age and Condition Restrictions:

Reflu is officially indicated for use only in the adult population (18 years of age and older); its use is not established and therefore not recommended for pediatric patients. The medicine is not recommended for patients with severe gastroparesis. Regarding pregnancy, official documents advise that the drug should be discontinued at least two months before a planned pregnancy and upon recognition of an established pregnancy.

What should I know about interactions with other medicines?

Reflu Interactions with other medicines and products

The interaction profile for the active ingredient in Reflu is primarily defined by its documented effect as a metabolic enzyme inhibitor. Officially, this medicine is classified as a potent inhibitor of CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4 (Pharmacokinetic Interaction). This inhibition can lead to increased systemic exposure of co-administered medicines.

Co-administration is strictly contraindicated in regulatory labeling with medicinal products such as Cisapride, Astemizole, Pimozide, Quinidine, and Erythromycin. The combination with Terfenadine is also prohibited at Fluconazole doses ge 400 mg/day. Use with Abrocitinib is officially stated to be avoided due to significant exposure increase.

The drug carries a documented pharmacodynamic risk of additive QT prolongation when co-administered with other medicinal products that affect the QT interval. This potential for cardiotoxicity leads to the combination with Halofantrine being explicitly not recommended.

Regarding exposure alteration, the AUC of Tofacitinib is increased by approximately 79%, and the prothrombin time (INR) for patients on Warfarin is increased. Conversely, co-administration with Rifampicin causes a 25% reduction in the AUC of Reflu. Food does not result in a clinically significant impairment of Reflu absorption. Interaction considerations are officially noted as heightened in patients with renal impairment due to altered drug clearance.

Mechanism of Action

The action of Reflu is based on disrupting the molecular and cellular biology of susceptible fungal cells. The mechanism involves a specific molecular cascade that results in the inhibition of fungal growth and proliferation.

Targeting the Fungal Ergosterol Pathway

The mechanism involves the selective inhibition of the fungal enzyme lanosterol 14-alpha-demethylase (CYP51). This enzyme is essential for catalyzing a required step in the biosynthesis of ergosterol. Ergosterol is the essential sterol component required to maintain the structural integrity and functionality of the fungal cell membrane. By binding to the target enzyme, the drug blocks this metabolic conversion process.

Destabilization and Fungistatic Effect

The enzyme blockade results in two critical physiological effects: the depletion of ergosterol and the accumulation of toxic methylated sterol precursors within the cell membrane. This combination causes the fungal membrane to lose its selective permeability and structural cohesion, leading to the leakage of essential cellular components. The resultant cellular damage and growth arrest produce a fungistatic effect, which is defined as the inhibition of the pathogen's proliferation.

Mechanistic Limitations: Resistance

The functional effectiveness of this mechanism can be constrained by the biological response of the fungal pathogen itself. This limitation arises when the fungus upregulates efflux pumps to actively transport the drug out of the cell, or when the target enzyme mutates, significantly reducing its binding affinity for the drug.

Dosage and Administration Information

How Reflu is Used: Administration Guidelines

The usage of Reflu (Fluconazole) is based on established administration principles that accommodate different clinical needs. The medicine is used via the oral route (capsules, tablets, and suspension) and the intravenous (IV) infusion route, with the daily dosage remaining the same regardless of the chosen method.

Dosing Patterns and Schedules

Administration often requires a loading dose—typically a higher initial amount (e.g., 200 mg to 400 mg)—on the first day to establish therapeutic plasma concentrations rapidly. This is followed by a maintenance dose, usually administered once daily. Treatment duration is tied to the specific fungal condition; regimens range from a single oral dose for acute localized infections to continuous, long-term suppressive therapy (e.g., 200 mg daily) to prevent relapse in vulnerable patients.

Preparation and Contextual Instructions

Instruction Category Procedural Detail
Intake Condition Oral formulations can be taken with or without food.
IV Administration The intravenous solution must be given as a slow infusion over approximately one hour, and not as a rapid bolus.
Dose Adjustment For multi-day regimens, the maintenance dose must be reduced by 50% in adult patients with renal impairment (CrCl 50 mL/min) after the initial loading dose.
Pediatric Use Dosing for pediatric patients is determined by body weight (mg/kg), following specific schedules.

The need for dose modification based on kidney function confirms that procedural adherence to the provided instructions is essential for proper administration.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Reflu (Fluconazole)

Evidence for Use in Systemic Fungal Infections

Research has extensively examined the agent’s role in conditions such as bloodstream infections (candidemia) and central nervous system infections (Cryptococcal Meningitis). For these areas, studies conducted include Randomized Controlled Trials (RCTs), where the agent was included in studies alongside other systemic agents.

In these trials, researchers monitored several key factors, including mycological clearance (whether the fungus was cleared from the blood or cerebrospinal fluid), and clinical success/response rate (observations of how symptoms evolved in the study populations). Studies monitored patterns of mycological clearance in the observed populations for certain systemic infections caused by susceptible Candida species. Research has also explored the agent's inclusion in longer-term consolidation and maintenance phases of Cryptococcal Meningitis research, where studies monitored recurrence over several months.

It is important to note that evidence is limited for some aspects of severe systemic infection. For example, data remain insufficient for certain types of Candida that are known to be less susceptible, such as C. glabrata. Furthermore, it is noted that studies have generally excluded patients who were severely neutropenic, meaning results apply only to the populations studied (primarily non-neutropenic adults).

Evidence for Use in Preventing Fungal Infections

Reflu was studied for its prophylactic role, meaning its use to prevent the development of a fungal infection in certain high-risk groups. The evidence base relies heavily on randomized, placebo-controlled trials and comprehensive systematic reviews.

Research examined the incidence of Invasive Fungal Infection (IFI)—the primary outcome—in populations particularly vulnerable to fungal diseases, such as extremely low birth weight neonates and adults undergoing intensive treatments. Studies monitored and recorded the incidence of IFI events across the tested groups and control groups over the study period. Studies also monitored overall survival during these periods, and trials generally reported no recorded difference in overall survival measurements.

Data for certain groups remain insufficient. Specifically, research exploring the agent’s role in infections in other types of immunocompromised patients, such as those with non-neutropenic malignancies or different chronic inflammatory conditions, is limited. Additionally, research is ongoing to determine the optimal length of time the preventive strategy should be used to achieve the desired outcomes while also avoiding potential effects on local microbial populations.

What Is Still Uncertain or Under Research

The research on Reflu contributes to the broader evidence landscape, but it also highlights areas where understanding is still developing. Comparative evidence is lacking for some of the newer antifungal agents across all approved indications. Ongoing research monitors patterns related to fungal resistance. Studies monitor the emergence of resistance patterns in Candida species following long-term or repeated observation, and the findings suggest continued surveillance. Overall, the evidence highlights what is known—and what is still uncertain—and these study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Reflu (FAQ)

Q: Does it make you sleepy?

According to the official product information, a common side effect of Reflu is somnolence (sleepiness) and dizziness. Official labeling notes that patients should avoid driving or operating complex machinery until they know how the medicine affects them.

Q: Can I drink alcohol while taking this?

Regulatory information indicates that alcohol should be avoided while taking Reflu. This combination can increase certain central nervous system (CNS) side effects of the medication, particularly feelings of sleepiness and dizziness.

Q: Is it safe to take while pregnant?

Official prescribing information indicates that Reflu may cause harm to a fetus. Women who can become pregnant are typically advised to use effective contraception throughout treatment. Its use during pregnancy is typically reserved for situations where the potential benefit to the mother justifies the potential risk to the fetus.

Q: How should I store this medication?

This medication is generally stored at room temperature, typically between 68 F and 77 F (20 C and 25 C). The product labeling specifies that Reflu should be kept in its original container and out of the sight and reach of children.

Q: What are the signs of a serious allergic reaction?

Serious allergic reactions, including angioedema (swelling beneath the skin), are noted in product information. If you experience symptoms like swelling of the face, mouth, tongue, or throat, or if you have trouble breathing, hives, or blisters, stop taking the medication immediately and seek emergency medical assistance.

Q: Can children 2 years old use it?

Official regulatory documents indicate that the use of this medication in children below a specific age (such as under 12 or 18 years old) for certain approved conditions has not been established or is not recommended. The prescribing information should be consulted for the specific age limits for each approved use.

How should Reflu be stored and disposed of?

How to Store and Dispose of Reflu

Storage of Reflu (Fluconazole) must adhere strictly to official labeled requirements to ensure stability. Capsules and tablets must be stored below 30 C (86 F), while the intravenous solution requires storage between 20 C and 25 C (68 F and 77 F). All formulations must be protected from freezing and excessive heat.

Keep the medicine in its original, tightly closed container and always keep Reflu out of the sight and reach of children.

Stability and Disposal

The reconstituted oral suspension must be discarded after two weeks. For disposal, unused or expired product should follow local official guidelines, and care must be taken to avoid environmental release into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Reflu found in:

A-Z Index: